Početna › Multipla skleroza › Arizona
Kliničke studije za Multipla skleroza u državi Arizona
6 studija za Multipla skleroza traži sudionike na lokacijama u državi Arizona.
Gradovi u državi Arizona
Službeni tekst studije (engleski)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Perseverance Research Center,LLC, Scottsdale
U tijeku regrutacijaFaza 2
Od 18 do 70 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Clinical Endpoints, LLC, Scottsdale
U tijeku regrutacijaFaza 4
Od 18 do 65 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07609719A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Gilbert
- TG Therapeutics Investigational Trial Site, Phoenix
- TG Therapeutics Investigational Trial Site, Scottsdale
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT06433752RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Arizona, Tucson
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 15. ruj 2026. · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195, Phoenix
- Perseverance Research Center- Site Number : 8400138, Scottsdale
U tijeku regrutacijaFaza 3
Od 18 do 60 godina · Oba spola · Ažurirano 15. ruj 2026. · NCT07325292A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Ctr for Neurology and Spine, Phoenix
- AZ Integrated Neuro and Spine, Phoenix
- Center for Neurosciences, Tucson
U tijeku regrutacijaFaza 3
Od 18 do 65 godina · Oba spola · Ažurirano 29. srp 2026. · NCT07225504Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.